Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Sorafenib vs Nexavar in Healthy Subjects
NCT02599337Phase 1Completed
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- Jul 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sorafenib in hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and thyroid cancer (2 arms), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoint: Bioequivalence (Cmax, AUC) at 96 hours. Started Jul 2015; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)thyroid cancer
Beyond the preview
Go deeper on NCT02599337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599337.